Liang Jian-Zhong, Li Yuan-Hua, Zhang Yu, Wu Qi-Nian, Wu Qiu-Liang
State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center Guangzhou, China ; Department of Pathology, Sun Yat-Sen University Cancer Center Guangzhou, China.
State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center Guangzhou, China ; Department of Nuclear Medicine, Sun Yat-Sen University Cancer Center Guangzhou, China.
Int J Clin Exp Pathol. 2015 Mar 1;8(3):2937-45. eCollection 2015.
The ETV6/TEL gene is a member of the ETS family of transcription factors that has been mainly studied in hematological diseases. This study provides the first investigation of ETV6 expression in non-small cell lung cancer (NSCLC). In this study, ETV6 expression was immunohistochemically studied in 170 consecutive patients with NSCLC. The association between ETV6 expression and clinicopathological parameters was evaluated. Kaplan-Meier survival analysis and Cox proportional hazards models were used to estimate the effect of ETV6 expression on survival. ETV6 expression was observed in 135 of the 170 (79.4%) patients. ETV6 expression was positive for nuclear staining. From the clinicopathological standpoint, the expression of ETV6 was significantly correlated with age (P=0.014). The overall survival was significantly enhanced in the group with a low expression of ETV6 compared with the group with a high expression of ETV6 (five-year survival rates, 56.53% versus 29.88%; P=0.002), and the same finding was obtained for disease-free survival (five-year survival rates, 52.24% versus 30.47%; P=0.001). Multivariable analysis confirmed that ETV6 expression increased the hazard of death after adjusting for other clinicopathological factors (hazard ratio, 2.002; 95% confidence interval, 1.303-3.074; P=0.002). Our study demonstrated that ETV6 was markedly involved in the development of NSCLC and could serve as a potential prognostic marker for this deadly disease.
ETV6/TEL基因是ETS转录因子家族的成员，主要在血液系统疾病中得到研究。本研究首次对非小细胞肺癌（NSCLC）中ETV6的表达进行了调查。在本研究中，对170例连续的NSCLC患者进行了ETV6表达的免疫组织化学研究。评估了ETV6表达与临床病理参数之间的关联。采用Kaplan-Meier生存分析和Cox比例风险模型来估计ETV6表达对生存的影响。在170例患者中的135例（79.4%）观察到ETV6表达。ETV6表达为细胞核染色阳性。从临床病理学角度来看，ETV6的表达与年龄显著相关（P=0.014）。与ETV6高表达组相比，ETV6低表达组的总生存期显著延长（五年生存率，56.53%对29.88%；P=0.002），无病生存期也有相同发现（五年生存率，52.24%对30.47%；P=0.001）。多变量分析证实，在调整其他临床病理因素后，ETV6表达增加了死亡风险（风险比，2.002；95%置信区间，1.303 - 3.074；P=0.002）。我们的研究表明，ETV6明显参与了NSCLC的发生发展，并且可以作为这种致命疾病的一个潜在预后标志物。
